Velcade(bortezomib)
Velcade (bortezomib) is a small molecule pharmaceutical. Bortezomib was first approved as Velcade on 2003-05-13. It is used to treat mantle-cell lymphoma and multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against proteasome subunit beta type-5. In addition, it is known to target proteasome subunit beta type-1.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Velcade (generic drugs available since 2022-05-02)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bortezomib
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
bortezomib | ANDA | 2022-06-01 |
velcade | New Drug Application | 2020-05-07 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Bortezomib, Bortezomib, Fresenius Kabi Usa | |||
8962572 | 2032-11-03 | DP |
Clinical
Clinical Trials
864 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | C90.0 | 109 | 212 | 87 | 9 | 25 | 388 | |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 14 | 13 | 4 | 1 | 2 | 31 | |
Waldenstrom macroglobulinemia | D008258 | C88.0 | 8 | 16 | 1 | 1 | 1 | 25 | |
Hematologic neoplasms | D019337 | 5 | 4 | — | 1 | 3 | 10 | ||
Kidney transplantation | D016030 | 2 | 3 | 1 | 1 | — | 5 | ||
Chronic renal insufficiency | D051436 | N18 | — | 1 | — | 1 | — | 2 | |
Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | — | 1 | 1 | 2 | |
Glycogen storage disease type ii | D006009 | Orphanet_365 | E74.02 | — | — | — | 1 | — | 1 |
Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | 1 | — | 1 |
Lupus nephritis | D008181 | EFO_0005761 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Mantle-cell lymphoma | D020522 | C83.1 | 21 | 32 | 3 | — | 1 | 48 | |
Lymphoma | D008223 | C85.9 | 21 | 29 | 1 | — | 1 | 47 | |
Non-hodgkin lymphoma | D008228 | C85.9 | 20 | 19 | 1 | — | 1 | 36 | |
Myeloid leukemia acute | D015470 | C92.0 | 15 | 10 | 1 | — | 1 | 24 | |
Large b-cell lymphoma diffuse | D016403 | C83.3 | 10 | 11 | 1 | — | 1 | 21 | |
Leukemia | D007938 | C95 | 11 | 8 | 1 | — | — | 18 | |
Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 6 | 2 | — | 3 | 11 |
Immunoglobulin light-chain amyloidosis | D000075363 | 2 | 4 | 4 | — | — | 10 | ||
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 1 | 1 | — | — | 2 |
Cholangiocarcinoma | D018281 | C22.1 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | C80 | 41 | 9 | — | — | — | 45 | |
Follicular lymphoma | D008224 | C82 | 10 | 18 | — | — | 2 | 27 | |
Plasma cell neoplasms | D054219 | 13 | 15 | — | — | — | 24 | ||
Non-small-cell lung carcinoma | D002289 | 7 | 16 | — | — | — | 21 | ||
Myelodysplastic syndromes | D009190 | D46 | 10 | 7 | — | — | 1 | 17 | |
B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 10 | 5 | — | — | 1 | 15 | |
Hodgkin disease | D006689 | C81 | 7 | 5 | — | — | — | 12 | |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 7 | 5 | — | — | — | 11 |
B-cell lymphoma marginal zone | D018442 | C88.4 | 6 | 4 | — | — | 1 | 11 | |
Lung neoplasms | D008175 | C34.90 | 8 | 6 | — | — | — | 11 |
Show 103 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Large-cell lymphoma anaplastic | D017728 | C84.6 | 5 | — | — | — | — | 5 | |
Lymphomatoid granulomatosis | D008230 | C83.8 | 4 | — | — | — | 1 | 5 | |
Large-cell lymphoma immunoblastic | D016400 | 3 | — | — | — | 1 | 4 | ||
Fallopian tube neoplasms | D005185 | 3 | — | — | — | — | 3 | ||
Anemia | D000740 | EFO_0004272 | D64.9 | 2 | — | — | — | — | 2 |
Intraocular lymphoma | D064090 | 1 | — | — | — | 1 | 2 | ||
Astrocytoma | D001254 | EFO_0000271 | 2 | — | — | — | — | 2 | |
Oligodendroglioma | D009837 | EFO_0000631 | 2 | — | — | — | — | 2 | |
Castration-resistant prostatic neoplasms | D064129 | 1 | — | — | — | — | 1 | ||
Myelomonocytic leukemia chronic | D015477 | C93.1 | 1 | — | — | — | — | 1 |
Show 32 more
Indications Without Phase
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | BORTEZOMIB |
INN | bortezomib |
Description | Bortezomib is l-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. It has a role as an antineoplastic agent, a proteasome inhibitor, a protease inhibitor and an antiprotozoal drug. It is an amino acid amide, a member of pyrazines and a L-phenylalanine derivative. It is functionally related to a boronic acid. |
Classification | Small molecule |
Drug class | proteozome inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O |
Identifiers
PDB | 5L5F |
CAS-ID | 179324-69-7 |
RxCUI | 358258 |
ChEMBL ID | CHEMBL325041 |
ChEBI ID | 52717 |
PubChem CID | 387447 |
DrugBank | DB00188 |
UNII ID | 69G8BD63PP (ChemIDplus, GSRS) |
Target
Agency Approved
PSMB5
PSMB5
Organism
Homo sapiens
Gene name
PSMB5
Gene synonyms
LMPX, MB1, X
NCBI Gene ID
Protein name
proteasome subunit beta type-5
Protein synonyms
Macropain epsilon chain, Multicatalytic endopeptidase complex epsilon chain, proteasome (prosome, macropain) subunit, beta type, 5, proteasome beta 5 subunit, proteasome catalytic subunit 3, Proteasome chain 6, Proteasome epsilon chain, proteasome subunit beta 5, Proteasome subunit MB1, Proteasome subunit X, proteasome subunit, beta type, 5, PSX large multifunctional protease X, testicular tissue protein Li 153
Uniprot ID
Mouse ortholog
Psmb5 (19173)
proteasome subunit beta type-5 (Q9R1P2)
Alternate
PSMB1
PSMB1
Organism
Homo sapiens
Gene name
PSMB1
Gene synonyms
PSC5
NCBI Gene ID
Protein name
proteasome subunit beta type-1
Protein synonyms
Macropain subunit C5, Multicatalytic endopeptidase complex subunit C5, proteasome (prosome, macropain) subunit, beta type, 1, proteasome beta 1 subunit, Proteasome component C5, Proteasome gamma chain, proteasome subunit beta 1, proteasome subunit beta6, proteasome subunit HC5, testicular secretory protein Li 45
Uniprot ID
Mouse ortholog
Psmb1 (19170)
proteasome subunit beta type-1 (Q62039)
Variants
Clinical Variant
No data
Financial
Velcade - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Velcade - Johnson & Johnson
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 35,600 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,953 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more